ProCE Banner Activity

KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC

Conference Coverage
Slideset

Prespecified exploratory biomarker analysis of KEYNOTE-522, presented at SABCS 2024, identified higher tumor mutation burden as predictive for event-free survival benefit from neoadjuvant and adjuvant pembrolizumab for triple-negative breast cancer. A further exploratory overall survival analysis found that the KEYNOTE-522 regimen shifted patients into lower residual cancer burden categories and improved overall survival across key subgroups defined by PD-L1 status, nodal status, overall disease status, and baseline T2N0 disease.

Released: December 16, 2024

Expiration: June 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation